Sim J - Search Results

1

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.

Chim CS, Lie AK, Chan EY, Liu HS, Lau CW, Yip SF, Sim J, Wan TS, Ma ES, Liang R, Tse E, Kwong YL; Hong Kong Society of Myeloma. Chim CS, et al. Among authors: sim j. J Hematol Oncol. 2012 Jun 8;5:28. doi: 10.1186/1756-8722-5-28. J Hematol Oncol. 2012. PMID: 22682027 Free PMC article.

2

BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.

Kwan TK, Ma ES, Chan YY, Wan TS, Liu HS, Sim JP, Yeung YM, Lie AK, Yip SF. Kwan TK, et al. Hong Kong Med J. 2009 Oct;15(5):365-73. Hong Kong Med J. 2009. PMID: 19801694 Free article.

3

Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.

Chim CS, Sim JP, Chan CC, Kho BC, Chan JC, Wong LG, Law M, Liang R, Kwong YL. Chim CS, et al. Among authors: sim jp. Hematology. 2010 Aug;15(4):187-92. doi: 10.1179/102453309X12583347113933. Hematology. 2010. PMID: 20670476

4

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.

Tse E, Leung AY, Sim J, Lee HK, Liu HS, Yip SF, Kwong YL. Tse E, et al. Among authors: sim j. Ann Hematol. 2011 Nov;90(11):1277-81. doi: 10.1007/s00277-011-1223-2. Epub 2011 Apr 1. Ann Hematol. 2011. PMID: 21455604 Free PMC article.

5

Histiocytic sarcoma simulating immune thrombocytopenic purpura.

Sim J, Hwang YY, Leung RY, So JC, Kwong YL. Sim J, et al. Ann Hematol. 2013 Apr;92(4):555-6. doi: 10.1007/s00277-012-1606-z. Epub 2012 Oct 18. Ann Hematol. 2013. PMID: 23076755 Free PMC article. No abstract available.

6

Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients.

Chan TS, Gill H, Hwang YY, Sim J, Tse AC, Loong F, Khong PL, Tse E, Leung AY, Chim CS, Lie AK, Kwong YL. Chan TS, et al. Among authors: sim j. Ann Hematol. 2014 Mar;93(3):493-8. doi: 10.1007/s00277-013-1882-2. Epub 2013 Aug 15. Ann Hematol. 2014. PMID: 23949318

7

LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.

Chim CS, Sim J, Tam S, Tse E, Lie AK, Kwong YL. Chim CS, et al. Among authors: sim j. Eur J Haematol. 2015 Apr;94(4):330-5. doi: 10.1111/ejh.12434. Epub 2014 Oct 18. Eur J Haematol. 2015. PMID: 25135740

8

Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.

Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY. Cher CY, et al. Among authors: sim jp. Blood Cancer J. 2016 Jul 8;6(7):e442. doi: 10.1038/bcj.2016.51. Blood Cancer J. 2016. PMID: 27391574 Free PMC article.

9

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation.

Chan TSY, Sim JPY, Kwong YL. Chan TSY, et al. Ann Hematol. 2017 Sep;96(9):1569-1572. doi: 10.1007/s00277-017-3033-7. Epub 2017 Jun 1. Ann Hematol. 2017. PMID: 28573313 No abstract available.

10

Favorable response of relapsed/refractory gray-zone lymphoma to brentuximab vedotin.

Li J, Sim J, Leung AYH, Kwong YL. Li J, et al. Among authors: sim j. Ann Hematol. 2018 Mar;97(3):551-554. doi: 10.1007/s00277-017-3179-3. Epub 2017 Dec 2. Ann Hematol. 2018. PMID: 29198035 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,832 results

Search Page